JP2021504466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504466A5 JP2021504466A5 JP2020545878A JP2020545878A JP2021504466A5 JP 2021504466 A5 JP2021504466 A5 JP 2021504466A5 JP 2020545878 A JP2020545878 A JP 2020545878A JP 2020545878 A JP2020545878 A JP 2020545878A JP 2021504466 A5 JP2021504466 A5 JP 2021504466A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- blocker
- compound
- pde2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000002876 beta blocker Substances 0.000 claims 10
- 229940097320 beta blocking agent Drugs 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 claims 6
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 claims 6
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 claims 6
- 239000003416 antiarrhythmic agent Substances 0.000 claims 5
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960002237 metoprolol Drugs 0.000 claims 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 239000002327 cardiovascular agent Substances 0.000 claims 2
- 229940125692 cardiovascular agent Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- AWJSRXUQLSPAOI-CQSZACIVSA-N n-[(1s)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl]-7-methoxy-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxamide Chemical compound C1([C@H](NC(=O)N2C3=NC=C(OC)C=C3NC(=O)C2)COC)=CC=C(OC(F)(F)F)C(F)=C1 AWJSRXUQLSPAOI-CQSZACIVSA-N 0.000 claims 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 claims 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- -1 Benzo [e]-[1,4] diazepine-5-yl Chemical group 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- MYTWFJKBZGMYCS-NQIIRXRSSA-N bay 60-7550 Chemical compound C1=C(OC)C(OC)=CC=C1CC(NN12)=NC(=O)C1=C(C)N=C2[C@H]([C@@H](C)O)CCCC1=CC=CC=C1 MYTWFJKBZGMYCS-NQIIRXRSSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 150000003943 catecholamines Chemical class 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000004731 long QT syndrome Diseases 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims 1
- 238000000899 pressurised-fluid extraction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188086A JP2024012483A (ja) | 2017-11-23 | 2023-11-02 | 頻脈の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203377.1 | 2017-11-23 | ||
| EP17203377 | 2017-11-23 | ||
| PCT/EP2018/082450 WO2019101970A1 (en) | 2017-11-23 | 2018-11-23 | Treatment of tachycardia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188086A Division JP2024012483A (ja) | 2017-11-23 | 2023-11-02 | 頻脈の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504466A JP2021504466A (ja) | 2021-02-15 |
| JP2021504466A5 true JP2021504466A5 (https=) | 2022-01-06 |
Family
ID=60452486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545878A Pending JP2021504466A (ja) | 2017-11-23 | 2018-11-23 | 頻脈の治療 |
| JP2023188086A Pending JP2024012483A (ja) | 2017-11-23 | 2023-11-02 | 頻脈の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188086A Pending JP2024012483A (ja) | 2017-11-23 | 2023-11-02 | 頻脈の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11419874B2 (https=) |
| EP (1) | EP3713572B1 (https=) |
| JP (2) | JP2021504466A (https=) |
| CN (1) | CN111447930A (https=) |
| AU (1) | AU2018371216B2 (https=) |
| CA (1) | CA3083176A1 (https=) |
| DK (1) | DK3713572T3 (https=) |
| ES (1) | ES3039584T3 (https=) |
| FI (1) | FI3713572T3 (https=) |
| PL (1) | PL3713572T3 (https=) |
| PT (1) | PT3713572T (https=) |
| WO (1) | WO2019101970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11219642B1 (en) * | 2020-09-01 | 2022-01-11 | Catherine Lueninghoener | Methods and compositions for treating heart conditions |
| CN113063804B (zh) * | 2021-03-16 | 2022-07-15 | 太原科技大学 | 一种基于图像处理的热切机视觉系统自动定位方法 |
| EP4334293A1 (en) * | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| EP1601675A1 (en) * | 2003-03-04 | 2005-12-07 | ALTANA Pharma AG | Purin-6-one-derivatives |
| AU2004268387A1 (en) | 2003-08-28 | 2005-03-10 | Nycomed Gmbh | Composition comprising a pulmonary surfactant and a PDE2 inhibitor |
| WO2005035505A2 (en) | 2003-09-30 | 2005-04-21 | Artesian Therapeutics, Inc. | Compounds with phosphodiesterase inhibiting and calcium channel blocking activities |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| ATE387446T1 (de) | 2003-12-16 | 2008-03-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| AU2005279221C9 (en) | 2004-09-02 | 2012-08-23 | Takeda Gmbh | Triazolophthalazines |
| EP1874775B1 (en) | 2005-01-05 | 2012-10-10 | Nycomed GmbH | Triazolophthalazines as pde2-inhibitors |
| BRPI0606379A2 (pt) | 2005-01-05 | 2009-06-23 | Nycomed Gmbh | triazolftalazinas |
| EP1749824A1 (en) | 2005-08-03 | 2007-02-07 | Neuro3D | Benzodiazepine derivatives, their preparation and the therapeutic use thereof |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| EP2279009A4 (en) * | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| US20100120762A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| SG195085A1 (en) | 2011-06-07 | 2013-12-30 | Pfizer | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| MX361539B (es) | 2012-04-25 | 2018-12-10 | Takeda Pharmaceuticals Co | Compuesto heterociclico nitrogenado. |
| EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| JPWO2015012328A1 (ja) | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| US10239882B2 (en) | 2014-11-05 | 2019-03-26 | Dart Neuroscience (Cayman) Ltd. | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors |
-
2018
- 2018-11-23 AU AU2018371216A patent/AU2018371216B2/en active Active
- 2018-11-23 CN CN201880078272.XA patent/CN111447930A/zh active Pending
- 2018-11-23 JP JP2020545878A patent/JP2021504466A/ja active Pending
- 2018-11-23 CA CA3083176A patent/CA3083176A1/en active Pending
- 2018-11-23 US US16/766,388 patent/US11419874B2/en active Active
- 2018-11-23 PT PT188046338T patent/PT3713572T/pt unknown
- 2018-11-23 ES ES18804633T patent/ES3039584T3/es active Active
- 2018-11-23 PL PL18804633.8T patent/PL3713572T3/pl unknown
- 2018-11-23 DK DK18804633.8T patent/DK3713572T3/da active
- 2018-11-23 WO PCT/EP2018/082450 patent/WO2019101970A1/en not_active Ceased
- 2018-11-23 FI FIEP18804633.8T patent/FI3713572T3/fi active
- 2018-11-23 EP EP18804633.8A patent/EP3713572B1/en active Active
-
2022
- 2022-07-18 US US17/866,795 patent/US20220362251A1/en not_active Abandoned
-
2023
- 2023-11-02 JP JP2023188086A patent/JP2024012483A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2894417C (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP5666910B2 (ja) | 認知機能障害を治療するためのキット、組成物、製品もしくは医薬 | |
| JP2021504466A5 (https=) | ||
| JP2010511701A5 (https=) | ||
| Mitsutake et al. | Usefulness of the Valsalva maneuver in management of the long QT syndrome. | |
| IL262708A (en) | Pretty metamorphous compounds of pyrazole for the treatment of diseases | |
| SE9901573D0 (sv) | New compounds | |
| JP2002275067A (ja) | 抗虚血薬剤 | |
| JP2016512198A5 (https=) | ||
| JP2015522592A5 (https=) | ||
| IL292739A (en) | Medical cognitive therapies | |
| CA2521182A1 (en) | Composition for improving cognition and memory | |
| KR20080025034A (ko) | Ｑｔ 간격 조절 방법 | |
| RU2003107668A (ru) | Новое оксабиспидиновое соединение, полезное при лечении сердечных аритмий | |
| MXPA03000439A (es) | Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. | |
| WO2014107685A2 (en) | Compositions and methods for using huperzine and analogs thereof | |
| CN111447930A (zh) | 心动过速的治疗 | |
| SE9901572D0 (sv) | New compounds | |
| WO2022031587A1 (en) | Use of cyclin-dependent kinase (cdk) inhibitors for the slowdown or prevention of biological aging | |
| JP2008543853A (ja) | プラスグレルのための薬剤投与計画 | |
| AR035807A1 (es) | Composicion farmaceutica de liberacion modificada apropiada para compuestos antiarritmicos, procedimiento para su preparacion, y uso de esta composicion para la manufactura de un medicamento para ser usado en la profilaxis o tratamiento de una arritmia | |
| Paclt et al. | Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram | |
| Taylor et al. | Agents for the treatment of congestive heart failure | |
| Carson et al. | Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis | |
| AU2015324072A1 (en) | A compound for anti-cancer therapy that acts by targeting GOF mutant P53 and stimulates P73 |